Oskar Vilhelmsson-Timmermand1, Elmer Santos2, Daniel L J Thorek3, Susan Evans-Axelsson4, Anders Bjartell4, Hans Lilja5, Steven M Larson2, Sven-Erik Strand1, Thuy A Tran6, David Ulmert7. 1. Department of Medical Radiation Physics, Lund University, Lund, Sweden. 2. Department of Radiology (Nuclear Medicine Service), Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 3. Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Clinical Sciences, Division of Urological Cancers, Lund University, Malmö, Sweden. 5. Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Departments of Laboratory Medicine and Medicine (GU Oncology), Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; Department of Laboratory Medicine, Lund University, Malmö, Sweden. 6. Department of Medical Radiation Physics, Lund University, Lund, Sweden; Lund University Bioimaging Center, Lund University, Lund, Sweden. 7. Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Clinical Sciences, Division of Urological Research, Lund University, Malmö, Sweden. Electronic address: ulmerth@mskcc.org.
Abstract
OBJECTIVES: Human tumors xenografted in immunodeficient mice are crucial models in nuclear medicine to evaluate the effectiveness of candidate diagnostic and therapeutic compounds. However, little attention has been focused on the biological profile of the host model and its potential effects on the bio-distribution and tumor targeting of the tracer compound under study. We specifically investigated the dissimilarity in bio-distribution of (111)In-DTPA-5A10, which targets free prostate specific antigen (fPSA), in two animal models. METHODS: In vivo bio-distribution studies of (111)In-DTPA-5A10 were performed in immunodeficient BALB/c-nu or NMRI-nu mice with subcutaneous (s.c.) LNCaP tumors. Targeting-specificity of the tracer was assessed by quantifying the uptake in (a) mice with s.c. xenografts of PSA-negative DU145 cells as well as (b) BALB/c-nu or NMRI-nu mice co-injected with an excess of non-labeled 5A10. Finally, the effect of neonatal Fc-receptor (FcRn) inhibition on the bio-distribution of the conjugate was studied by saturating FcRn-binding capacity with nonspecific IgG1. RESULTS: The inherent biological attributes of the mouse model substantially influenced the bio-distribution and pharmacokinetics of (111)In-DTPA-5A10. With LNCaP xenografts in BALB/c-nu mice (with intact B and NK cells but with deficient T cells) versus NMRI-nu mice (with intact B cells, increased NK cells and absent T cells), we observed a significantly higher hepatic accumulation (26 ± 3.9 versus 3.5 ± 0.4%IA/g respectively), and concomitantly lower tumor uptake (25 ± 11 versus 52 ± 10%IA/g respectively) in BALB/c-nu mice. Inhibiting FcRn by administration of nonspecific IgG1 just prior to (111)In-DTPA-5A10 did not change tumor accumulation significantly. CONCLUSIONS: We demonstrated that the choice of immunodeficient mouse model importantly influence the bio-distribution of (111)In-DTPA-5A10. This study further highlighted important considerations in the evaluation of preclinical tracers, with respect to gaining information on their performance in the translational setting. Investigators utilizing xenograft models need to assess not only radiolabeling strategies, but also the host immunological status.
OBJECTIVES:Humantumors xenografted in immunodeficientmice are crucial models in nuclear medicine to evaluate the effectiveness of candidate diagnostic and therapeutic compounds. However, little attention has been focused on the biological profile of the host model and its potential effects on the bio-distribution and tumor targeting of the tracer compound under study. We specifically investigated the dissimilarity in bio-distribution of (111)In-DTPA-5A10, which targets free prostate specific antigen (fPSA), in two animal models. METHODS: In vivo bio-distribution studies of (111)In-DTPA-5A10 were performed in immunodeficient BALB/c-nu or NMRI-nu mice with subcutaneous (s.c.) LNCaPtumors. Targeting-specificity of the tracer was assessed by quantifying the uptake in (a) mice with s.c. xenografts of PSA-negative DU145 cells as well as (b) BALB/c-nu or NMRI-nu mice co-injected with an excess of non-labeled 5A10. Finally, the effect of neonatal Fc-receptor (FcRn) inhibition on the bio-distribution of the conjugate was studied by saturating FcRn-binding capacity with nonspecific IgG1. RESULTS: The inherent biological attributes of the mouse model substantially influenced the bio-distribution and pharmacokinetics of (111)In-DTPA-5A10. With LNCaP xenografts in BALB/c-nu mice (with intact B and NK cells but with deficient T cells) versus NMRI-nu mice (with intact B cells, increased NK cells and absent T cells), we observed a significantly higher hepatic accumulation (26 ± 3.9 versus 3.5 ± 0.4%IA/g respectively), and concomitantly lower tumor uptake (25 ± 11 versus 52 ± 10%IA/g respectively) in BALB/c-nu mice. Inhibiting FcRn by administration of nonspecific IgG1 just prior to (111)In-DTPA-5A10 did not change tumor accumulation significantly. CONCLUSIONS: We demonstrated that the choice of immunodeficientmouse model importantly influence the bio-distribution of (111)In-DTPA-5A10. This study further highlighted important considerations in the evaluation of preclinical tracers, with respect to gaining information on their performance in the translational setting. Investigators utilizing xenograft models need to assess not only radiolabeling strategies, but also the host immunological status.
Authors: K Pettersson; T Piironen; M Seppälä; L Liukkonen; A Christensson; M T Matikainen; M Suonpää; T Lövgren; H Lilja Journal: Clin Chem Date: 1995-10 Impact factor: 8.327
Authors: Kirstin A Zettlitz; Wen-Ting K Tsai; Scott M Knowles; Felix B Salazar; Naoko Kobayashi; Robert E Reiter; Anna M Wu Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Daniel L J Thorek; Anson T Ku; Nicholas Mitsiades; Darren Veach; Philip A Watson; Dipti Metha; Sven-Erik Strand; Sai Kiran Sharma; Jason S Lewis; Diane S Abou; Hans G Lilja; Steven M Larson; Michael R McDevitt; David Ulmert Journal: Clin Cancer Res Date: 2018-09-25 Impact factor: 12.531
Authors: Dmitry Pankov; Ludvig Sjöström; Teja Kalidindi; Sang-Gyu Lee; Kjell Sjöström; Rui Gardner; Michael R McDevitt; Richard O'Reilly; Daniel L J Thorek; Steven M Larson; Darren Veach; David Ulmert Journal: Oncotarget Date: 2017-07-26